4-(4-(1-isopropyl-7-oxo-1,4,6,7-tetrahydrospiro[indazole-5,4'-piperidine]-1'-carbonyl)-6-methoxypyridin-2-yl)benzoicacid

4-(4-(1-isopropyl-7-oxo-1,4,6,7-tetrahydrospiro[indazole-5,4'-piperidine]-1'-carbonyl)-6-methoxypyridin-2-yl)benzoicacid Property

Boiling point:

745.3±60.0 °C(Predicted)

Density 

1.36±0.1 g/cm3(Predicted)

storage temp. 

Store at -20°C

solubility 

DMSO: 100 mg/mL (198.98 mM);Ethanol: 5 mg/mL (9.95 mM)

pka

3.93±0.10(Predicted)

Water Solubility 

Water: Insoluble

InChIKey

LXZMHBHEXAELHH-UHFFFAOYSA-N

SMILES

C(O)(=O)C1=CC=C(C2=NC(OC)=CC(C(N3CCC4(CC3)CC(=O)C3=C(C4)C=NN3C(C)C)=O)=C2)C=C1

Hazard and Precautionary Statements (GHS)

4-(4-(1-isopropyl-7-oxo-1,4,6,7-tetrahydrospiro[indazole-5,4'-piperidine]-1'-carbonyl)-6-methoxypyridin-2-yl)benzoicacid Chemical Properties,Usage,Production

Description

PF-05221304 is an inhibitor of acetyl-CoA carboxylase 1 (ACC1) and ACC2 (IC50s = 12.4 and 8.7 nM, respectively).1 It inhibits de novo lipid synthesis (IC50 = 61 nM) and increases fatty acid oxidation in primary human hepatocytes. PF-05221304 reduces the accumulation of triglycerides composed of de novo-derived fatty acids but not dietary essential fatty acids in primary human hepatocytes. In vivo, PF-05221304 (10 and 100 mg/kg) reduces hepatic malonyl-CoA production and de novo lipogenesis in rats. It reduces hepatic fibrosis, alanine transaminase (ALT) and aspartate aminotransferase (AST) levels, and triglyceride accumulation in a rat model of non-alcoholic steatohepatitis (NASH) induced by a choline-deficient and high-fat diet (CDAHFD).WARNING This product is not for human or veterinary use.